W Zhou1,2, Y Liu2, X Guo2, H Yang3, Y Xu4, D Geng5. 1. Department of Orthopedics, The First Affiliated Hospital of University of Science and Technology of China, 17, Lu Jiang Road, Hefei, 230001, People's Republic of China. 2. Department of Orthopedics, The First Affiliated Hospital of Soochow University, 188, Shi Zi Road, Suzhou, 215006, People's Republic of China. 3. Department of Orthopedics, The First Affiliated Hospital of Soochow University, 188, Shi Zi Road, Suzhou, 215006, People's Republic of China. Soochowspine@sina.com. 4. Department of Orthopedics, The First Affiliated Hospital of Soochow University, 188, Shi Zi Road, Suzhou, 215006, People's Republic of China. xuyaozeng@163.com. 5. Department of Orthopedics, The First Affiliated Hospital of Soochow University, 188, Shi Zi Road, Suzhou, 215006, People's Republic of China. szgengdc@163.com.
Abstract
INTRODUCTION: To investigate the effect of zoledronic acid on periprosthetic bone mineral density (BMD) and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis. METHODS:From November 2015 to April 2016, 40 female patients who met the inclusion criteria were randomized into two groups: a control group (calcium + calcitriol) and a zoledronic acid group (calcium + calcitriol + zoledronic acid). At 1 week and 3, 6, and 12 months after operation, BMD was obtained through dual-energy X-ray absorptiometry (DEXA). At pre-operation and at 3, 6, and 12 months after the operation, levels of bone metabolism markers were obtained by serum examination. RESULTS:Loss of BMD was significantly more pronounced in the control group than in the ZOL group in zones 1, 4, 6, and 7 at 6 months and in zones 1, 2, 4, 6, and 7 at 12 months after the operation. The levels of bone-resorption marker (β-CTX) were significantly lower in the ZOL group than in the control group at 3, 6, and 12 months after operation. The levels of bone-formation marker (TP1NP) performed statistically differences only at 12 months after the operation in these two groups. CONCLUSIONS: Receiving an intravenous infusion of 5 mg zoledronic acid after THA can effectively reduce periprosthetic BMD loss and improve bone remodeling in females with postmenopausal osteoporosis. Zoledronic acid significantly inhibited bone mass loss in zones 1, 2, 4, 6, and 7 after THA and inhibited bone-resorption marker (β-CTX) to improve bone remodeling. Zoledronic acid treatment is potentially important for patients with osteoporosis after THA.
RCT Entities:
INTRODUCTION: To investigate the effect of zoledronic acid on periprosthetic bone mineral density (BMD) and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis. METHODS: From November 2015 to April 2016, 40 female patients who met the inclusion criteria were randomized into two groups: a control group (calcium + calcitriol) and a zoledronic acid group (calcium + calcitriol + zoledronic acid). At 1 week and 3, 6, and 12 months after operation, BMD was obtained through dual-energy X-ray absorptiometry (DEXA). At pre-operation and at 3, 6, and 12 months after the operation, levels of bone metabolism markers were obtained by serum examination. RESULTS: Loss of BMD was significantly more pronounced in the control group than in the ZOL group in zones 1, 4, 6, and 7 at 6 months and in zones 1, 2, 4, 6, and 7 at 12 months after the operation. The levels of bone-resorption marker (β-CTX) were significantly lower in the ZOL group than in the control group at 3, 6, and 12 months after operation. The levels of bone-formation marker (TP1NP) performed statistically differences only at 12 months after the operation in these two groups. CONCLUSIONS: Receiving an intravenous infusion of 5 mg zoledronic acid after THA can effectively reduce periprosthetic BMD loss and improve bone remodeling in females with postmenopausal osteoporosis. Zoledronic acid significantly inhibited bone mass loss in zones 1, 2, 4, 6, and 7 after THA and inhibited bone-resorption marker (β-CTX) to improve bone remodeling. Zoledronic acid treatment is potentially important for patients with osteoporosis after THA.
Entities:
Keywords:
Bone metabolism markers; Bone mineral density; Postmenopausal osteoporosis; Zoledronic acid
Authors: G H Nancollas; R Tang; R J Phipps; Z Henneman; S Gulde; W Wu; A Mangood; R G G Russell; F H Ebetino Journal: Bone Date: 2005-07-20 Impact factor: 4.398
Authors: Monti Khatod; Maria C S Inacio; Richard M Dell; Stefano A Bini; Elizabeth W Paxton; Robert S Namba Journal: Clin Orthop Relat Res Date: 2015-11 Impact factor: 4.176
Authors: Henrik S G Bodén; Olof G Sköldenberg; Mats O F Salemyr; Hans-Jerker Lundberg; Per Y Adolphson Journal: Acta Orthop Date: 2006-12 Impact factor: 3.717
Authors: Maurizio Muratore; Eugenio Quarta; Laura Quarta; Fabio Calcagnile; Antonella Grimaldi; M Antonio Orgiani; Antonio Marsilio; Giuseppe Rollo Journal: Clin Cases Miner Bone Metab Date: 2012-05-29
Authors: Christopher L McDonald; Nicholas J Lemme; Edward J Testa; Roy Aaron; Davis A Hartnett; Eric M Cohen Journal: Arthroplast Today Date: 2022-03-15